2012-11-13T15:12:02-06:00 2011-12-31 410746749 CLIFTONLARSONALLEN LLP 20 E THOMAS RD STE 2300 PHOENIX AZ 85012 990 2011-01-01 861024333 THE INTERNATIONAL GENOMICS CONSORTIUM INTE 6028507000 445 NORTH FIFTH STREET NO 300 PHOENIX AZ 85004 DAVID W NEAL CPA 6028507000 2012-11-13 1 PHIL MCCOLLUM P00129716 6022662248 2011 2016-02-24 21:20:13Z DR ROBERT PENNY 445 NORTH FIFTH STREET NO 300 PHOENIX AZ 85004 10056319 0 X WWW.INTEGEN.ORG X 2001 AZ THE MISSION OF IGC IS TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES BY RIGOROUSLY DEVELOPING AND APPLYING POST-GENOME SCIENCE TO ADVANCES IN HUMAN HEALTH. 4 2 63 0 0 0 1000000 1000000 7218654 8577607 6482 7907 475829 470805 8700965 10056319 0 0 0 0 4933076 5682591 0 0 0 3744588 3623967 8677664 9306558 23301 749761 5998097 6728467 1863037 2277551 4135060 4450916 X THE MISSION OF IGC IS TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES BY RIGOROUSLY DEVELOPING AND APPLYING POST-GENOME SCIENCE TO ADVANCES IN HUMAN HEALTH. 1 0 5860623 5932153 THE CANCER GENOME ATLAS/BIOSPECIMEN CORE RESOURCE-THE CANCER GENOME ATLAS (TCGA), JOINTLY SPONSORED BY THE NATIONAL CANCER INSTITUTE (NCI) AND THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI), IS A LARGE-SCALE GENOMICS PROJECT WITH THE AMBITIOUS GOAL OF CREATING AN "ATLAS" OF THE CANCER GENOME. IGC IS THE BIOSPECIMEN CORE RESOURCE (BCR) FOR TCGA AND SERVES AS A CENTRALIZED LABORATORY/REPOSITORY THAT REVIEWS AND PROCESSES ALL CANCER AND NORMAL TISSUE SAMPLES (BLOOD INCLUDED) AND THEIR ASSOCIATED CLINICAL DATA USING RIGOROUS STANDARD OPERATING PROCEDURES FOR TCGA RESEARCH NETWORK. ALL DATA COLLECTED IS POSTED TO A PUBLICLY ACCESSIBLE GOVERNMENT WEBSITE, FREE OF ANY INTELLECTUAL PROPERTY RESTRICTIONS. 1610902 2444853 THE CANCER GENOME ATLAS/TISSUE SOURCE SITE NETWORK-IN ADDITION TO ITS FUNCTION AS A BCR, IGC IS ESTABLISHING A NETWORK OF TISSUE SOURCE SITES CAPABLE OF DELIVERING HIGH QUALITY, CLINICALLY ANNOTATED CANCER TISSUE SAMPLES INTO THE TCGA PROJECT. THE INITIAL PHASE OF THE PROJECT CALLS FOR COLLECTION OF 8475 SAMPLES OF NUMEROUS CANCER TYPES. IGC IDENTIFIES AND CONTRACTS WITH CANCER CENTERS THROUGHOUT THE WORLD, TRAINS THE SITES IN ALL ASPECTS OF PATIENT CONSENT, TISSUE COLLECTION AND PRESERVATION, SHIPMENT AND FOLLOW UP COLLECTION OF CLINICAL DATA. 116191 116191 ARIZONA BIOSIGNATURES ALLIANCE-THE ARIZONA BIOSIGNATURES ALLIANCE IS EXPLORING THE NEED FOR VALIDATING ASSAYS FOR BIOMARKERS FOR THE BIOSCIENCE INDUSTRY IN ACCORDANCE WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES AND OTHER REGULATORY GUIDELINES SUCH AS THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA). THE AIM IS TO BRING PRECISION AND ROBUSTNESS TO DIAGNOSITCS USED IN CLINICAL TRIALS AND PATIENT TESTING AT HOSPITALS AND LABORATORIES AROUND THE WORLD. 1344 84410 EXPRESSIONS IN ONCOLOGY PROJECT-IGC CONTINUED ITS EXPRESSIONS IN ONCOLOGY PROJECT (EXPO). THE ONGOING MISSION OF THE EXPRESSIONS PROJECT FOR ONCOLOGY (EXPO) MISSION IS TO BUILD ON THE TECHNOLOGIES AND OUTCOMES OF THE HUMAN GENOME PROJECT AND OTHER COMPREHENSIVE RESEARCH EFFORTS SUCH AS THE CANCER GENOME ATLAS PROJECT (TCGA) TO ACCELERATE IMPROVED CLINICAL MANAGEMENT OF CANCER PATIENTS. AS PART OF THE MISSION, IGC CREATED AND CONTINUES TO MAINTAIN A DATABASE OF THE GENE EXPRESSION PROFILES OF HUMAN TUMOR TISSUE AND NORMAL TISSUES CLINICALLY ANNOTATED AND DE-IDENTIFIED FOR PUBLIC ACCESS. IGC STEWARDS THE USE AND REDISTRIBUTION OF EXPO RESOURCES (TUMOR TISSUE, NORMAL TISSUE, TISSUE ADJACENT TO TUMOR, PERIPHERAL BLOOD LYMPHOCYTE CNA AND SERUM) TO ACCELERATE RESEARCH AND ULTIMATELY IMPROVE CLINICAL MANAGEMENT OF CANCER PATIENTS. 1344 84410 7589060 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 28 0 1 63 1 0 0 0 0 0 0 0 0 0 0 X 4 2 1 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 AZ X DAVID W NEAL CPA 6028507006 445 N 5TH STREET SUITE 300 PHOENIX AZ 85004 RICHARD MALLERY ESQ 1.00 X 0 0 0 RUSSELL RICHARDSON 1.00 X 0 0 0 ROBERT J PENNY MDPHD 40.00 X X 632218 0 22868 DAVID MALLERY 40.00 X X 329656 0 18344 DANIEL VON HOFF MD 1.00 X 0 90000 0 DAVID W NEAL 40.00 X 148511 0 16578 ERIN CURLEY 25.00 X 132987 0 10400 WILLIAM TROY SHELTON 40.00 X 158618 0 5602 MARK SHERMAN 40.00 X 159170 0 13936 JOSEPH PAULAUSKIS 40.00 X 187664 0 12862 PEGGY YENA 40.00 X 109595 0 18042 1858419 90000 118632 9 0 1 0 SNELL & WILMER LLP ONE ARIZONA CENTER PHOENIX AZ 85004 LEGAL SERVICES 294905 1 1000000 1000000 CONTRACT REVENUE 541711 8577607 8577607 8577607 7907 7907 463361 0 463361 463361 463361 OTHER INCOME 900099 7444 7444 7444 10056319 8577607 0 478712 1110385 832721 277664 3777886 3069775 708111 107233 71320 35913 369352 250532 118820 317735 110258 207477 336719 243901 92818 37874 10775 27099 807119 803124 3995 28534 28534 249886 218669 31217 37651 37651 739935 604325 135610 135451 124594 10857 23006 4800 18206 324364 308801 15563 56141 50527 5614 LAB SUPPLIES AND CONSUM 847287 847287 9306558 7589060 1717498 0 647415 1256247 717750 1001178 2141139 1707235 1454527 1519395 175394 162143 2929774 1930335 830074 999439 24291 31798 58539 5998097 6728467 1163363 1792188 263710 187337 435964 298026 1863037 2277551 X 2320526 3066394 1814534 1384522 4135060 4450916 5998097 6728467 X 749761 -433905 X X 0 1 1 X 0 X SCOTTSDALE HEALTHCARE HOSPITALS SCOTTSDALE AZ RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2879619 1880180 999439 50155 50155 0 999439 DUE TO RELATED PARTIES 298026 298026 10056319 9306558 749761 -433904 -59642 -493546 256215 10166317 49387 60611 109998 10056319 0 10056319 9910102 483291 120253 603544 9306558 0 9306558 PART XI, LINE 8 - OTHER ADJUSTMENTS: NET LOSS ATTRIBUTABLE TO IMC REPORTED ON SEPARATE RETURN -59,641. ROUNDING -1. TOTAL TO SCHEDULE D, PART XI, LINE 8: -59,642. PART XII, LINE 2D - OTHER ADJUSTMENTS: ICG MANAGEMENT CORP REVENUES INCLUDED IN CONSOLIDATED FINANCIAL STATEMENTS 60,611. PART XIII, LINE 2D - OTHER ADJUSTMENTS: ICG MANAGEMENT CORP EXPENSES INCLUDED IN CONSOLIDATED FINANCIAL STATEMENTS 120,252. ROUNDING 1. X 1 1 X X X X 0 0 0 0 0 0 0 0 0 ROBERT J PENNY MDPHD 632218 0 0 0 0 0 8932 0 13936 0 655086 0 0 0 DAVID MALLERY 329656 0 0 0 0 0 4778 0 13566 0 348000 0 0 0 DAVID W NEAL 148511 0 0 0 0 0 6732 0 9846 0 165089 0 0 0 WILLIAM TROY SHELTON 158618 0 0 0 0 0 0 0 5602 0 164220 0 0 0 MARK SHERMAN 159170 0 0 0 0 0 0 0 13936 0 173106 0 0 0 JOSEPH PAULAUSKIS 187664 0 0 0 0 0 8001 0 4861 0 200526 0 0 0 PART I, LINE 1B FROM THE BENEFIT OF FREQUENT FLYER MILES THE CEO QUALIFIES FOR FIRST-CLASS UPGRADES AT MINIMAL OR NO COST. IN ALL OTHER INSTANCES WRITTEN TRAVEL POLICY IS FOLLOWED. RICHARD MALLERY SERVES AS BOARD CHAIRMAN 294905 PARTNER IN LAW FIRM THAT PROVIDES LEGAL SERVICES TO IGC. 0 NEW PROGRAM SERVICES FORM 990, PART III, LINE 2 ARIZONA BIOSIGNATURES ALLIANCE- THE ARIZONA BIOSIGNATURES ALLIANCE IS EXPLORING THE NEED FOR VALIDATING ASSAYS FOR BIOMARKERS FOR THE BIOSCIENCE INDUSTRY IN ACCORDANCE WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES AND OTHER REGULATORY GUIDELINES SUCH AS THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA). THE AIM IS TO BRING PRECISION AND ROBUSTNESS TO DIAGNOSITCS USED IN CLINICAL TRIALS AND PATIENT TESTING AT HOSPITALS AND LABORATORIES AROUND THE WORLD. FORM 990, PART VI, SECTION A, LINE 2 DAVID MALLERY HAS A FAMILY AND BUSINESS RELATIONSHIP WITH RICHARD MALLERY. RICHARD MALLERY (CHAIRMAN OF IGC'S BOARD OF DIRECTORS) AND DAVID MALLERY (PRESIDENT OF IGC) ARE FATHER AND SON. ROBERT PENNY AND DAVID MALLERY HAVE A BUSINESS RELATIONSHIP WITH SHELBY SCHARBACH. MARICOPA COUNTY HAS A MULTI-YEAR ECONOMIC FUNDING AGREEMENT WITH IGC, WHICH INCLUDES A PROVISION FOR A NON-VOTING OBSERVER TO BE IN ATTENDANCE AT IGC BOARD MEETINGS. SHELBY SCHARBACH, CFO FOR MARICOPA COUNTY, IS THE DESIGNATED OBSERVER. FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES THAT HAVE AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11 990 WILL BE REVIEWED BY THE CFO, AND THEN A DRAFT WILL BE PRESENTED TO THE BOARD BEFORE BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE POLICY REQUIRES THE DISCLOSURE OF ANY POTENTIAL CONFLICTS. ANY REPORTED CONFLICTS ARE REVIEWED BY UNINTERESTED MEMBERS OF THE BOARD OF DIRECTORS. THESE CONFLICTS ARE THEN MONITORED AND MANAGED BY THE PRESIDENT AND/OR CEO. IN ADDITION, IF A RELEATED PARTY AGREEMENT IS PROPOSED, THE BOARD IS REQUIRED TO INVESTIGATE ALTERNATIVES BEFORE THEY WILL APPROVE SUCH AN AGREEMENT AS IN THE BEST INTERESTS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION DATA WAS OBTAINED FROM SEVERAL COMPENSATION SURVEYS ON SIMILAR POSITIONS IN OTHER FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS. EDUCATION, EXPERIENCE AND FAMILIARITY WITH IGC'S TARGETED CLIENTELE WERE THEN FACTORED IN TO THE SUGGESTED COMPENSATION RANGES. FINAL COMPENSATION AMOUNTS WERE REVIEWED, APPROVED AND FORMALLY DOCUMENTED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 WE DO NOT MAKE OUR GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: DONATED SERVICES AND USE OF FACILITIES: -433,904. ROUNDING -1. TOTAL TO FORM 990, PART XI, LINE 5: -433,905. FORM 990, PART XII, LINE 2C THE COMMITTEE ASSUMES RESPONSIBILITY OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. FORM 990, PAGE 5, QUESTIONS 7G AND H THE ORGANIZATION DID NOT RECEIVE THE TYPES OF CONTRIBUTIONS LISTED AND, THEREFORE, DOES NOT HAVE EITHER A FORM 8899 OR A FORM 1098-C FILING REQUIREMENT. THEREFORE, THESE QUESTIONS ARE LEFT BLANK BECAUSE THEY ARE NOT APPLICABLE AND THE ANSWER IS NEITHER YES OR NO. IGC MANAGEMENT SERVICES LLC 445 N 5TH ST SUITE 300 PHOENIX AZ 85004 800361103 INVESTMENT IN IGC MGMT CORPORATION AZ 0 24291 IGC IGC MANAGEMENT CORPORATION 445 N 5TH STREET SUITE 300 PHOENIX AZ 85004 453017176 BIOBANKING AZ IMS LLC C 67982 50808 1.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 IGC MANAGEMENT CORPORATION N 0